GlassScriptPhysician profile
Jason B Green
NPI 1427167261
$213,083.21
in general payments reported to CMS, 2019-2025
40 companies · $104K in 2025
The $104K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,991 · 2021: $8,005 · 2022: $1,445 · 2023: $13K · 2024: $54K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $74K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Debt Forgiveness: $30K · Food and Beverage: $10K · Travel and Lodging: $4,411 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $74,295.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,535.00 |
| Debt Forgiveness | $30,200.00 |
| Food and Beverage | $10,225.75 |
| Travel and Lodging | $4,411.48 |
| Education | $364.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $57,638.98 | 2023-2025 | |
| Leo Pharma INC. | $50,435.41 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $22,671.12 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $16,977.80 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Celgene Corporation | $14,642.66 | 2019 | |
| Almirall LLC | $11,148.61 | 2019-2024 | Klisyri |
| Ucb, INC. | $10,317.65 | 2020-2025 | Bimzelx, Cimzia |
| Medimetriks Pharmaceuticals, INC. | $10,050.00 | 2020-2025 | Neo-Synalar, Genadur, Tovet (Emollient Formulation) |
| Amgen INC. | $8,390.08 | 2020-2023 | Otezla |
| Genzyme Corporation | $3,644.21 | 2019-2025 | |
| Pfizer INC. | $1,101.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,039.61 | 2020-2025 | Dupixent |
| Abbvie INC. | $958.86 | 2019-2025 | |
| Biofrontera INC. | $627.67 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $505.26 | 2020-2025 | Tremfya |
Show all 38 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.